Phenominer Database Results (22 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Record ID Study ID
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 27 14.0 d 1.06 5.5 in vivo visual assessment 0.0 70194 1301
DA/ZtmKini spleen weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. spleen mass male  days 8 0.18 % 0.0 0.01 post excision weight measurement 0.0 84931 1301
DA/ZtmKini liver weight to body weight ratio control condition Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. liver mass male  days 8 32.73 g/kg 0.79 2.24 post excision weight measurement 0.0 84938 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female  days 24 91.7 % in vivo visual assessment 0.0 84466 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 27 96.3 % in vivo visual assessment 0.0 70188 1301
DA/ZtmKini inguinal lymph node wet weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. inguinal lymph node mass male  days 8 0.68 g/kg 0.07 0.21 post excision weight measurement 0.0 84927 1301
DA/ZtmKini inguinal lymph node wet weight to body weight ratio control condition Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. inguinal lymph node mass male  days 8 0.15 g/kg 0.01 0.02 post excision weight measurement 0.0 84928 1301
DA/ZtmKini plasma orosomucoid 1 level control condition Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. orosomucoid 1 amount male  days 8 93.0 mg/l 8.13 23.0 radial immunodiffusion assay 0.0 84934 1301
DA/ZtmKini liver weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. liver mass male  days 8 28.96 g/kg 0.64 1.8 post excision weight measurement 0.0 84933 1301
DA/ZtmKini spleen weight to body weight ratio control condition Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. spleen mass male  days 8 0.17 % 0.0 0.01 post excision weight measurement 0.0 84936 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male  days 24 100.0 % in vivo visual assessment 0.0 84465 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male  days 24 14.6 d 1.39 6.8 in vivo visual assessment 0.0 84467 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 6 16.3 d 0.94 2.3 in vivo visual assessment 0.0 84472 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 5 100.0 % in vivo visual assessment 0.0 70192 1301
DA/ZtmKini plasma orosomucoid 1 level Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. orosomucoid 1 amount male  days 8 419.0 mg/l 82.02 232.0 radial immunodiffusion assay 0.0 84929 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female  days 24 14.6 d 0.63 3.1 in vivo visual assessment 0.0 84468 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 6 100.0 % in vivo visual assessment 0.0 84470 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 5 12.2 d 0.18 0.4 in vivo visual assessment 0.0 70196 1301
DA/ZtmKini thymus weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. thymus mass male  days 8 0.6 mg/g 0.07 0.19 post excision weight measurement 0.0 84932 1301
DA/ZtmKini thymus weight to body weight ratio control condition Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. thymus mass male  days 8 1.22 mg/g 0.1 0.29 post excision weight measurement 0.0 84937 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 15 93.0 % in vivo visual assessment 0.0 84469 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both  days 15 14.9 d 1.52 5.9 in vivo visual assessment 0.0 84471 1301